Interferon-free, direct-acting antiviral therapy for chronic hepatitis C.
about
Interferon-Free Treatments for Chronic Hepatitis C Genotype 1 InfectionCombination ledipasvir-sofosbuvir for the treatment of chronic hepatitis C virus infection: a review and clinical perspectiveRecent advances in understanding hepatitis CHepatitis C virus: Promising discoveries and new treatmentsTreatment of Hepatitis C in Patients Undergoing Immunosuppressive Drug TherapyLimiting the access to direct-acting antivirals against HCV: an ethical dilemma.Disease Burden, Early Discontinuation, and Healthcare Costs in Hepatitis C Patients with and without Chronic Kidney Disease Treated with Interferon-Free Direct-Acting Antiviral Regimens.Effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir for hepatitis C virus in clinical practice: A population-based observational study.Estimating the Impact of Expanding Treatment Coverage and Allocation Strategies for Chronic Hepatitis C in a Direct Antiviral Agent EraNS3 Resistance-Associated Variants (RAVs) in Patients Infected with HCV Genotype 1a in SpainNaturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C.Improving Viral Protease Inhibitors to Counter Drug Resistance.Predictors of early treatment discontinuation and severe anemia in a Brazilian cohort of hepatitis C patients treated with first-generation protease inhibitors.HCV core protein inhibits polarization and activity of both M1 and M2 macrophages through the TLR2 signaling pathway.Simultaneous determination of newly developed antiviral agents in pharmaceutical formulations by HPLC-DAD.Estimation of direct medical cost related to the management of chronic hepatitis C and its complications in South Korea.Safety of new DAAs for chronic HCV infection in a real life experience: role of a surveillance network based on clinician and hospital pharmacistEconomic study of the value of expanding HCV treatment capacity in Germany.Effectiveness of interferon-free therapy for the treatment of HCV-patients with compensated cirrhosis treated through the Irish early access program.High prevalence of willingness to use direct-acting antiviral-based regimens for hepatitis C virus (HCV) infection among HIV/HCV coinfected people who use drugs.Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients.Characterization of clinical predictors of naturally occurring NS3/NS4A protease polymorphism in genotype 1 hepatitis C virus mono and HIV co-infected patients.Real-world challenges for hepatitis C virus medications: a critical overview.HCV Integrated Care: A Randomized Trial to Increase Treatment Initiation and SVR with Direct Acting Antivirals.Effect of Steady-State Faldaprevir on Pharmacokinetics of Atorvastatin or Rosuvastatin in Healthy Volunteers: A Prospective Open-Label, Fixed-Sequence Crossover Study.Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy.A highly specific and sensitive hepatitis C virus antigen enzyme immunoassay for One-step diagnosis of viremic hepatitis C virus infection.Simeprevir/pegylated interferon/ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation.Predictors Associated with Increase in Skeletal Muscle Mass after Sustained Virological Response in Chronic Hepatitis C Treated with Direct Acting Antivirals.The HepTestContest: a global innovation contest to identify approaches to hepatitis B and C testing.Efficacy and safety of sofosbuvir-based therapies in patients with advanced liver disease in a real-life cohort.Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study.Viral Hepatitis in South Korea
P2860
Q26746563-5E3926C4-730A-4C41-A36B-B72B1344E344Q26746910-2A00FE58-0C8E-4D4C-A50D-4E47F274F19EQ26766136-68C6A3B4-8778-44E0-AEFF-6E69D5DD68AEQ27468916-858EB25A-7403-41AF-B080-294AD4CEBFC4Q28073100-9120ABEF-63AB-41BC-9BBF-6622FF0FB43CQ30244361-D5B18B2B-2B0B-4F0D-9D79-312EE736A427Q33845581-C8EF0F8C-C2EA-4D12-B5C7-3288520FD045Q33883646-8971BBE5-34EC-4DE7-984C-40C735C0C086Q36133794-11E80F0D-CA32-41C5-9C01-571ED8010B0CQ36148440-54CDF591-4167-43A3-ABF4-65497434339EQ36292486-64252198-908D-4467-BFB4-DC1597BD7753Q37017282-1F8D030C-9863-4C9A-AB57-36922368A887Q37050953-8E3BCC0C-E7C0-43B7-8EAC-039148E3454FQ37370720-E24EACF8-24B0-4426-8F36-9D15F5767CB3Q37559735-58AD0E51-13A4-4EB5-802C-98706DD8E179Q37605535-E17637BE-6070-4221-BCB4-F670761B422DQ37630878-7B0E5075-6FA5-4C91-8037-184315411F64Q38688748-A90B059F-3366-40AC-BB2F-007DB9DB8D1AQ38748387-C1BE17B5-B3C5-43D1-9731-636C84397C56Q38907436-91D05E2D-E1DC-4D77-B45D-DF78FE4AE5A6Q39062828-118F0155-3412-4380-9450-E6757522F9D7Q39182744-FA6131F8-5FB1-4B67-B93D-DEA50EAC3F47Q39326974-E7E4B3DF-83E1-491C-AFD8-C55ED9032BCCQ40078740-5633CF67-DB8C-43CD-8420-9B8C4B0F2AC3Q40198351-B2FD0139-E2D1-4B3C-9D85-7675B840ACD2Q40593610-67700EAF-D62C-4FF9-B2CE-6B5366122D20Q40641577-46275C39-1541-4D30-AAD4-A3CD0ECD4A92Q40923578-3EFF39F3-6E82-48E9-BB01-031F93BA6010Q45372289-E41D6E0D-1518-4912-B259-BB1EC0C548E6Q46490867-779920F2-C228-4765-B4F1-0B945D6F35F2Q47098950-B9704213-31B5-4002-8962-D0E7FD31BA28Q55050518-CE572E1E-60BE-447F-A7DD-6DABD1341B40Q57212111-820529E1-093E-4FF9-BA24-AA688D478C1A
P2860
Interferon-free, direct-acting antiviral therapy for chronic hepatitis C.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Interferon-free, direct-acting antiviral therapy for chronic hepatitis C.
@en
type
label
Interferon-free, direct-acting antiviral therapy for chronic hepatitis C.
@en
prefLabel
Interferon-free, direct-acting antiviral therapy for chronic hepatitis C.
@en
P2093
P2860
P356
P1476
Interferon-free, direct-acting antiviral therapy for chronic hepatitis C.
@en
P2093
E J Lawitz
J A Gutierrez
P2860
P304
P356
10.1111/JVH.12422
P577
2015-06-17T00:00:00Z